Forced Vital Capacity
Lysophosphatidic acid receptor 1 antagonist slows time to disease progression in IPF
SAN DIEGO — Taking an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks slowed time to disease progression in idiopathic pulmonary fibrosis, according to a presentation at the American Thoracic Society International Conference.
Adults with food insecurity have reduced lung function, elevated COPD symptom burden
SAN DIEGO — Lung function decreased and COPD symptom burden increased among adults with vs. without food insecurity, according to research presented at the American Thoracic Society International Conference.
Race-neutral equations for COPD trial eligibility may lead to more Black patients enrolled
SAN DIEGO — Using race-neutral equations to determine eligibility for COPD clinical trials may lead to higher percentages of Black patients enrolled, according to a poster presented at the American Thoracic Society International Conference.
Tool predicts new-onset exertional, resting hypoxemia in patients with fibrotic ILD
A tool that includes age, BMI, two lung function measures and a diagnosis of idiopathic pulmonary fibrosis can predict new-onset exertional and resting hypoxemia in fibrotic interstitial lung disease, according to study results.
Zinpentraxin alfa comparable to placebo in idiopathic pulmonary fibrosis
Among patients with idiopathic pulmonary fibrosis, lung function decline was comparable between 52-week zinpentraxin alfa treatment and placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.
Lysophosphatidic acid receptor 1 antagonist slows lung function decline in progressive PF
Receiving an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks lowered the rate of percent predicted FVC decline in progressive pulmonary fibrosis, according to a European Respiratory Society International Congress presentation.
Nintedanib slows loss of lung function in limited cutaneous systemic sclerosis, ILD
Nintedanib slows the deterioration of lung functionality in patients with limited cutaneous systemic sclerosis and interstitial lung disease, according to data published in Rheumatology.
Occupational exposures to gases, dust, fumes linked to reduced lung function
Researchers observed a decline in lung function, measured by FEV1, among those who were exposed to gases, dusts, fumes and aromatic solvents at work, according to a study published in Occupational & Environmental Medicine.
Researchers characterize patients who might benefit from early COPD intervention
Individuals with low FEV1/FVC ratio plus low FVC lifetime trajectories were at an increased risk for COPD, according to a study in The Lancet Respiratory Medicine.
Prenatal phthalate exposure reduces lung function in childhood
Gestational exposure to phthalates was linked to lower FVC and FEV1 during childhood, particularly early childhood, with four phthalates demonstrating a significant association, concluded recent results.